论文部分内容阅读
应用~(126)I-UdR释放法,检测58例淋巴瘤病人及52例正常人外周血自然杀伤细胞(NK)活性。治疗前和复发病人NK活性分别为39.56±13.45％和43.31±13.30％,均明显低于正常人(58.01±8.21％)。Ⅲ～Ⅳ期病人NK活性(34.72±12.6％)明显低于Ⅰ～Ⅱ期病人(45.47±11.63％);伴有全身症状的病人(31.38±11.43％)明显低于无全身症状病人(45.91±11.45％)。NK活性与治疗效果有关。治疗后完全缓解者NK活性恢复正常,部分或未缓解者则无明显改善。NK活性与淋巴瘤组织类型无关。
The natural killer (NK) activity in peripheral blood of 58 patients with lymphoma and 52 normal controls was detected by ~ (126) I-UdR release assay. The NK activity of patients before and after treatment were 39.56 ± 13.45% and 43.31 ± 13.30%, respectively, which were significantly lower than that of normal people (58.01 ± 8.21%). Patients with stage Ⅲ ~ Ⅳ NK activity (34.72 ± 12.6%) were significantly lower than those with stage Ⅰ ~ Ⅱ (45.47 ± 11.63%). Patients with systemic symptoms (31.38 ± 11.43%) were significantly lower than those without systemic diseases (45.91 ± 11.45%). NK activity and treatment effect. NK response to complete remission after treatment returned to normal, with or without partial or no improvement. NK activity and lymphoma tissue type has nothing to do.